To prove this, we preincubated CLL cells expressing high levels of CD69 (> 30%) with ibrutinib 1 μM or idelalisib 0.5 μM for 24 hours before adding bendamustine for 24 additional hours. This evidence concerns the gene CD69 and B-cell chronic lymphocytic leukemia.